Dashboard
Manage Tickers

ATNM Actinium Pharmaceuticals, Inc.

NYSE actiniumpharma.com


$ 1.34 $ -0.01 (-0.74 %)    

Wednesday, 05-Nov-2025 15:49:55 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 622.38 $ 4.94 (0.8 %)
DIA $ 473.04 $ 2.23 (0.47 %)
SPY $ 677.28 $ 2.47 (0.37 %)
TLT $ 89.01 $ -0.57 (-0.64 %)
GLD $ 365.20 $ 0.10 (0.03 %)
$ 1.34
$ 1.33
$ 1.32 x 50
$ 1.41 x 100
$ 1.33 - $ 1.36
$ 1.03 - $ 2.41
89,863
na
41.8M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 04-26-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-25-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 07-30-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 10-23-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 06-30-2020 03-31-2020 10-Q
23 05-08-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 03-15-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-16-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 08-04-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-29-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 10-30-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

actinium-to-present-new-breast-cancer-data-on-its-atnm-400-radiotherapy-at-san-antonio-symposium
Actinium To Present New Breast Cancer Data...
11/04/2025 12:34:15

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development...

actinium-pharma-presents-preclinical-data-of-atnm-400-in-non-small-cell-lung-cancer-at-aacr-nci-eortc-international-conference
Actinium Pharma Presents Preclinical Data ...
10/27/2025 11:17:33

-  ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EG...

actinium-pharmaceuticals-presents-new-preclinical-data-for-atnm-400-antibody-radioconjugate-at-32nd-annual-prostate-cancer-foundation-scientific-retreat-in-carlsbad-california
Actinium Pharmaceuticals Presents New Prec...
10/24/2025 12:31:58

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated ...

actinium-pharmaceuticals-announces-that-the-first-ever-preclinical-data-from-its-atnm-400-program-in-non-small-cell-lung-cancer-has-been-accepted-for-presentation-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-being-held-october-22--26-2025
Actinium Pharmaceuticals Announces That Th...
10/13/2025 16:14:35

NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM), a leader in the development of differentiat...

actinium-pharma-reports-additional-preclinical-data-supporting-atnm-400-radiotherapy-prostate-cancer-candidate-at-annual-trp-summit
Actinium Pharma Reports Additional Preclin...
07/31/2025 12:33:43

-     ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto® and enzalutam...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
06/24/2025 10:57:49

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...

actinium-pharma-reports-new-preclinical-data-from-non-psma-targeting-radiotherapy-prostate-cancer-candidate-atnm-400-at-snmmi-annual-meeting
Actinium Pharma Reports New Preclinical Da...
06/23/2025 15:33:14

-  ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ab...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
05/12/2025 16:15:11

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...

actinium-announces-enrollment-of-first-patient-in-the-iomab-act-commercial-car-t-trial-at-the-university-of-texas-southwestern-medical-center-initial-clinical-data-expected-in-the-second-half-of-2025
Actinium Announces Enrollment Of First Pat...
05/06/2025 12:48:07

-       Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted ra...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
04/28/2025 17:28:02

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...

actinium-pharma-announces-atnm-400-preclinical-data-highlighting-sustained-tumor-control-and-safety-for-prostate-cancer-patients-post-pluvicto
Actinium Pharma Announces ATNM-400 Preclin...
04/28/2025 12:39:50

-  Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet cl...

actinium-highlights-mutation-agnostic-antileukemic-activity-of-actimab-a-against-flt3-npm1-kmt2a-and-tp53-mutations-in-aml-models-demonstrating-backbone-potential-for-acute-myeloid-leukemia-treatment
Actinium Highlights Mutation Agnostic Anti...
04/28/2025 12:12:45

Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hy...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
04/01/2025 11:12:44

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
03/27/2025 17:16:36

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...

actinium-provides-business-update-detailing-recent-achievements-and-anticipated-milestones-from-its-clinical-pipeline
Actinium Provides Business Update Detailin...
03/27/2025 11:40:29

The update featured the unveiling of ATNM-400, Actinium's new Actinium-225 (Ac-225) solid tumor program, which is a novel, ...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
03/26/2025 17:05:38

actinium-pharmaceuticals-to-present-business-update-at-trump-mar-a-lago-club-today-revitalized-clinical-programs-focused-on-3-separate-market-opportunities-in-myeloid-malignancies-solid-tumors-and-cell--gene-therapy-conditioning-with-clinical-data-expected-in-2025
Actinium Pharmaceuticals To Present Busine...
03/26/2025 12:47:06

- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
03/25/2025 15:44:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...

actinium-pharmaceuticals-enters-agreement-with-eckert--ziegler-for-supply-of-actinium-225-to-develop-actimab-a-and-other-candidates-for-us-and-international-trials-terms-not-disclose
Actinium Pharmaceuticals Enters Agreement ...
03/24/2025 20:17:07

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, ...

hc-wainwright--co-reiterates-buy-on-actinium-pharma-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Acti...
03/20/2025 15:14:11

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION